The UAE healthcare sector is one of the fastest-growing in the GCC, driven by UAE Vision 2031 health strategy, mandatory health insurance, growing medical tourism, and significant privatisation of healthcare delivery. Corvian Advisory provides specialist M&A advisory and independent valuation for UAE healthcare businesses, including hospitals, polyclinics, diagnostic centres, home care providers, dental chains, HealthTech, and pharma distributors. CFA-led. Fixed fee.
Healthcare M&A in the UAE demands sector-specific expertise beyond financial modelling, licence transfer planning, payor mix analysis, consultant tenure risk, and an acquirer universe spanning PE funds, sovereign investors, hospital groups, and insurance companies.
Full sell-side for UAE healthcare businesses (hospitals, clinic chains, home care, diagnostics), valuation, CIM with healthcare KPIs, structured outreach to PE, hospital groups, and GCC sovereign investors, through to close.
IVS-compliant valuation using EV/EBITDA multiples (typically 6x–14x for UAE healthcare), DCF, and NAV. Includes DHA/HAAD licence value, patient database intangible, and brand value where applicable. Fixed fee.
Buy-side advisory for PE, hospital groups, and corporates acquiring UAE healthcare assets, target identification, clinical and financial due diligence coordination, licence transfer planning (DHA/HAAD/MOH), and deal structuring.
M&A advisory and ARR-based valuation for UAE HealthTech businesses, EMR/EHR platforms, telehealth, hospital management software, digital health apps, and medtech.
Buy-side FDD for healthcare acquisitions, revenue quality by payor mix, working capital normalisation for medical consumables, regulatory compliance review, and EBITDA normalisation for consultant fee structures.
Capital raising for UAE healthcare businesses, equity and debt advisory for clinic roll-ups, hospital expansions, and HealthTech fundraising from GCC family offices, PE funds, and sovereign-linked investors.
Healthcare M&A in the UAE has sector-specific nuances general M&A advisors consistently underestimate. These are the deal dynamics that determine whether a transaction closes, and at what multiple.
DHA and HAAD licences, and specialist consultant authorisations, are the most valuable intangibles in many UAE healthcare acquisitions. Licence transfer adds 60–90 days and requires MOH/DHA/HAAD approval, the most common reason UAE healthcare deals stall.
Clinic chains and hospitals with high Thiqa (HAAD) or Daman insurance revenue command a premium over pure self-pay businesses. Government and quasi-government insurance contracts are sticky and directly lift the multiple.
Gulf Capital, Investcorp, Waha Capital, and Mubadala Health have all made significant UAE healthcare acquisitions, a preferred PE vertical due to defensive revenue and population growth demand.
UAE clinic chains (dental, physiotherapy, aesthetics, GP polyclinics) trade at a 30–50% premium to single-site businesses of the same EBITDA. Founders with 3+ sites should position as a roll-up platform, not individual clinics.
Dubai has invested significantly in becoming a regional medical tourism hub. Hospitals and specialist clinics serving MENA, Africa, and CIS patients command a premium for this diversified revenue base.
Hospital groups acquiring EMR and telehealth platforms, insurance companies acquiring health data technology, and global HealthTech firms acquiring MENA regulatory knowledge. NABIDH compliance is increasingly an acquirer requirement.
CFA-led M&A advisory and independent healthcare business valuation. Fixed fee. DHA, HAAD, and MOH licence transfer expertise included.